Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant

NCT ID: NCT01506375

Last Updated: 2014-05-26

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-11-30
• Study Completion Date: 2013-04-30

Brief Summary

The aim of the study is to compare the safety, clinical tolerability, immunogenicity and efficacy of gpASIT+TM (grass pollen peptides) alone and combined with an immunoregulating adjuvant, in a short course administration (5 injections over 4 weeks).

Conditions

Hay Fever

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

gpASIT

grass pollen peptides alone

Group Type: EXPERIMENTAL

gpASIT+TM

Intervention Type: BIOLOGICAL

1 subcutaneous injection every 7 days during 29 days

gpASIT/adjuvant

grass pollen peptides + adjuvant

Group Type: EXPERIMENTAL

gpASIT+TM + adjuvant

Intervention Type: BIOLOGICAL

1 subcutaneous injection every 7 days during 29 days

Interventions

gpASIT+TM

1 subcutaneous injection every 7 days during 29 days

Intervention Type: BIOLOGICAL

gpASIT+TM + adjuvant

1 subcutaneous injection every 7 days during 29 days

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Subject has given written informed consent
• Age between 18 and 50 years
• The subjects are in good physical and mental health according to his/her medical history, vital signs, and clinical status
• Male or non-pregnant, non-lactating female
• Females unable to bear children must have documentation of such in the CRF (i.e. tubule ligation, hysterectomy, or post-menopausal (defined as a minimum of one year since the last menstrual period))
• Allergy diagnosis:

• A medical history of moderate to severe seasonal allergic rhinoconjunctivitis (SAR) during the grass pollen season during at least the two previous years
• A positive skin prick test (wheal diameter ≥ 3 mm) to grass-pollen mixture
• Specific IgE against grass pollen (IgE > 0.7 kU/l) [using recombinant mixture of rPhl p1 and rPhl p5b Phleum pratense (g213)]
• Subjects never treated by immunotherapy or subjects for whom the immunotherapy ended at December 31, 2009 and who had as well moderate to severe symptoms in the two previous years (2010 and 2011)

Exclusion Criteria

• Subjects with current immunotherapy and subjects who underwent a previous immunotherapy within the last 2 years
• Participation in another clinical trial and/or treatment with an experimental drug within the last 3 months
• A history of hypersensitivity to the excipients of investigational products
• Subjects with perennial asthma (regular intake of inhaled corticosteroids outside the pollen season: consumption on a daily base or patients who are taking a reliever more than twice a week)
• Subjects with severe seasonal asthma requiring long acting beta agonist AND inhaled steroid treatment
• Subjects with a VC < 80% and a FEV1 < 70% of predicted value at the screening visit
• Subjects symptomatic to perennial inhalant allergens who should need antihistamine drug or systemic corticoids to relieve allergic symptoms during the treatment period
• Subjects with documented evidence of chronic sinusitis (as determined by Investigator)
• Subjects with rhinitis medicamentosa, non-specific rhinitis (to food dye, preservative agent…)
• Subjects with a history of renal disease or chronic hepatic disease
• Subject with malignant disease, autoimmune disease
• Any chronic disease, which may impair the subject's ability to participate in the trial
• Subjects requiring beta-blockers medication
• Chronic use of concomitant medications that would affect assessment of the effectiveness of the trial medication (e.g. tricyclic antidepressants)
• Regular consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs within 4 weeks preceding the trial (screening visit)
• Any consumption of corticoids (oral, topic or nasal) or of anti-histaminic drugs within 1 week preceding the trial (screening visit)
• Subject with febrile illness (> 37.5°C, oral)
• A known positive serology for HIV-1/2, HBV or HCV
• Subjects that are immunocompromised by medication or illness, have received a vaccine, corticoids or immunosuppressive medications within 1 month before trial entry
• Receipt of blood or a blood derivative in the past 6 months preceding trial entry
• Female subjects who are pregnant, lactating, or of child-bearing potential and not protected from pregnancy by a sufficiently reliable method
• Any condition which could be incompatible with protocol understanding and compliance
• Subjects who have forfeited their freedom by administrative or legal award or who are under guardianship
• Unreliable subjects including non-compliant subjects, subjects with known alcoholism or drug abuse or with a history of a serious psychiatric disorder as well as subjects unwilling to give informed consent or to abide by the requirements of the protocol
• Subjects without means of contacting the Investigator rapidly in case of emergency, or not able to be contacted rapidly by the Investigator

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BioTech Tools S.A.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Universitaire Ziekenhuis van Leuven

Leuven, , Belgium

Countries

Belgium

Other Identifiers

2011-004486-33

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

gpASIT006

Identifier Type: -

Identifier Source: org_study_id